A while back I posted my favorite stocks and NVGN is my favorite stock. Last year the charts P&F pointed to $30 bucks and since I have posted it, it is now up over 50% in one week.
The best cancer company PERIOD, bar None.
The CEO even cured himself with an Older version of one of their many drugs and he had the cancer spread to his bones.
Last year this company was a $16 million market cap...now over $70 million and heading for a Billion. There will be plenty of opportunities in my opinion to buy this much cheaper, because there are Gaps everywhere and the candle on Thursday appeared to look like a reverse is close, just on a technical side. Fundamentally it is very strong, but CEO Kelly has taken advantage of these runs with dilution, not much, but enough to allow growth.
Very Smart CEO and they have partnerships with almost all the popular Universities that specialize in Pharma.
A very strategic plan and there company will surpass SYN even if we get $100 million upfront cash with double digit royalties...that is how much I like their medicines.
CTIX --- my second favorite cancer company that is small.
TRIL --- third cancer company that is small.
TGTX --- they will likely be acquired either later this year or next year.
LPCN --- oral testosterone that is safer than the gels, but investors have feared investing due to another company that was rejected because of heart complications and many do not believe it will be approved. I do believe it has the best chance and it will Double for SURE before their PDUFA date.
CFRX --- unbelievable technology on killing the toughest to kill bacteria.
SNTA--- it is nothing like NVGN, but they should easily double this year prior to news on Ganetespib for multiple cancers.
AVXL --- it's just flat out undervalued and until the IBB crashes or begins a major correction I see this one continuing to climb. Aricept currently with sales of around $4 Billion combined with Avxl's drug produced great results..promising!
That is a very intelligent way to accumulate this, as being a Long Term Holder.
Next year I plan on doing a study in one stock and allowing some money just to sit and on the other hand putting my skills to the ultimate test to measure the difference.
SYN is super volatile and provides an ATM for chart traders because it really has Never had a sustained run...it has Always pulled back.
Will that change?
It all depends on the Trimesta deal. That is what could change this company for good.
If the deal is not that good, expect more of the same volatility, except with a lot more shares.
The dilution for over 650,000 shares at 2.06 I'm not a fan of, but they must of Really needed the money.
That's one thing I am concerned about in the future...dilution at low prices. I have seen it destroy some stocks that once had nice potentials....then they end up in BKrupt or in penny land.
This stock needs a good sustainable run to over $5.
One more thing to mention that is of importance: Syn-004 is being measured in two separate doses: (1) BID low dose and (2) BID high dose
So I have a feeling they are doing more than stated here...but they definitely want to prove that the high doses do not disrupt the antibiotic in the blood.
That is exactly what I was thinking and it will probably be measured, but it says nothing about this in the clinical trials site that I can find.
In fact I didn't even see a Secondary Objective which is very strange...but you can count on this being measured also.
Your Question: Wasn't plasma concentrations addressed in phase I? I know they HAVE tested this, but I am not familiar with how they did it right off hand. SYN is doing this the right way and moving fairly swift about it by confirming the plasma level. FDA Loves repeated confirmations.
After this, then comes the POC test and results expected at the end of year. As Riley stated "this will definitely be an EVENTFUL year".
That should be a nice catalyst for the stock price.
Here is Exactly what they said:
"We are pleased to announce that a Clinical Trial Phase II-A trial has commenced and we expect results Late in the Second Quarter of this year. AFTER this is the Phase II-B Proof of Concept or POC trial. This is to be launched in the Second Half of this year with Top Line Data due by the End of the Year. SYN-004 will be undergoing regulatory reviews for several Years before commercialization. "
They are figuring out when the levels of the antibiotic ceftriaxone peaks in the blood with and without syn's drug. They want to make sure that Sure that the drug doesn't interfere with plasma levels of that particular antibiotic.
According to SYN the drug should NOT interfere at all with Ceftriaxone in the blood, but just work in the part of the gut intended...ileum to disable the antibiotic to protect the mircrobiome.
This is a confirmation test. So it will be good to get this over with and confirmed to move onward.
Yeah, biotime (btx) used to play that one last year...almost forgot all about it.
Wow, it has had a good run. SYN could have this also.
Wow I predicted Momenta would be bought by NVS
TEVA has been exploring options as they know their revenues will soon be Cut and they have to do Something. Mylan and Momenta was in a race to see who could get their generic Copaxone out first. That would make one huge Generic Company. Teva is about twice the size, so it would have to be some kind of merger rather than flat out acquisition.
Both with MS drugs --- it appears TEVA Really wants to stay in the MS game very, very badly!
I can't believe how well SYN has held up so far. We are currently in between a gap and not moving...wow. Probably should of waited to buy, but will likely be gone most of next week.
Now I am half way worried about the market and if I should even be in this. The gravity of the downswing in DOW and IBB will eventually have a force on everything. I really don't like the timing.
The DOW was predicted to begin to fall on Monday by many, a day early I guess. Should of went with my gut on the VIX, still may.
I was looking at the VIX last night and thinking everything is not so peachy in Greece, earnings have not been good-even though most have met expectations but analysts were ordered to lower expectations and sell it as good news to the public....it won't be long until people realize what is going on.
The VIX could explode.
Excellent Call so far. I had more orders at 2.37 and 2.34 and now one for 3,000 at 2.28.
Still Very Bullish long term Weekly Chart.
When I say soon I mean it will in the next two weeks. They still could play cat and mouse with it.
I play ONCS a lot also, played them the last time they hit .33 and bounced to .40, I sold at .39. That one I would NEVER trade without chart knowledge...Way too Risky, unless you are in a breakout and can just join the momentum.
It is getting close to bottoming out.
The bad thing about ONCS is that the dang dilution. The tech is probably worth it, but the dilution just breaks the heart, but every dog has his day and ONCS will once again reverse, but it may hit .27 first.
This could be us in two months.
I sold all my CYTR to come here...now I wish I would of held CYTR...one thing about CUR, GALE, RXII and CYTR is that you are prone to AF's major short bashing attacks.
At least he hasn't attacked SYN yet.
Yeah, I commented on it.
This dumb board, there is either something inefficient with their software...don't know what's going on, but they delete a LOT of posts. They may have deleted it if you copied and pasted anything that was copyright?
That's why NVS could be a player which I have posted a few times.
Sandoz partnered with Momenta. I believe that Momenta will be acquired--- eventually...
Dallas you have to remember this is a NON- Technical board. Fanelli, Success, Victor, You and Myself. I won't post technical stuff unless others do as it is very interesting to me --- but we all are under fire on this board, some others just ridicule it and are going down a one way road. They have to WANT to learn and they have to Believe in it. They think TA is like Santa Claus.
I just happen to be one of the few that Believe in a LOT of different things that 90% of the population wouldn't understand, nor attempt to understand.